DOCSLIB.ORG

Diffuse Lung Infiltration in a Homosexual Man Without AIDS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diffuse Lung Infiltration in a Homosexual Man Without AIDS Diffuse lung infiltration in a homosexual man without AIDS RICHARD POHIL, MD PHILIP MAPLE, MD GILBERT DALONZO, DO Homosexual men who present Physical examination on admission revealed the pa- with respiratory complaints and diffuse tient to be well developed and healthy appearing. The lung infiltrates on chest x-ray generally oral temperature was 100F, and the respiratory rate have the AIDS syndrome and an ongoing was 22 breaths/min; otherwise, his vital signs were nor- opportunistic pneumonia. In the case mal. Bibasilar mid-to-end inspiratory crackles were presented, the usual diagnosis was not heard on auscultation. There was no evidence of ade- found and the patients lung infiltrates and nopathy, abdominal organ enlargement, or skin lesions, and the oral and rectal examinations had normal find- symptoms were due to drug-induced ings. eosinophilic pneumonia. This case report Diffuse, bilateral, interstitial-alveolar infiltrates were demonstrates that not all homosexual men demonstrated on the chest roentgenogram (Fig 1). The who present with the usual clinical picture electrocardiogram was normal. Values for arterial P02, for AIDS have AIDS and that not all diffuse PCO2, and pH were 60 mm Hg, 34 mm Hg, and 7.41, lung infiltrates are infectious in etiology. respectively. The peripheral leukocyte count was 12,000/ cu mm. The differential count included 66% eosinophils; the total eosinophil count was 80,000/cu mm. A homosexual man with diffuse pulmonary in- Based on presumptive diagnosis of Pneumocystis car- filtrates, cough, and hypoxemia usually is thought inii pneumonia, the patient initially was treated with to have acquired immunodeficiency syndrome an intravenous trimethoprim and sulfamethoxazole com- (AIDS). In such cases, the pulmonary infiltrates bination. The next morning, approximately 14 hours fol- are considered to be of infectious origin; Pneumocys- lowing admission, bronchoscopy, bronchoalveolar lavage, tis carinii, 1 cytomegalovirus, 2 and nontubercular and multiple transbronchial biopsy were performed un- mycobacterial infections3 generally are suspected. der fluoroscopic guidance. The case reported here demonstrates that not Histologic examination of the biopsy specimens re- all homosexual men who present with the classic vealed only marked eosinophilic infiltration (Fig 2). Bron- clinical picture have AIDS, and that not all diffuse choalveolar lavage failed to reveal an infectious etiol- ogy. Routine and special cultures for fungus, virus, lung infiltrates are infectious in etiology. Chla- mydia, Mycoplasma, Legionella, and Mycobacterium Report of case were negative. Stool specimens, as well as a duodenal aspirate, failed to demonstrate ova or parasites. There A 25-year-old homosexual man was admitted in August was no deficiency of helper T-lymphocytes, and the T- 1984 for evaluation of a productive cough with clear spu- cell helper/suppressor ratio in the peripheral blood was tum, bilateral pleuritic chest pain, and exertional dysp- normal. nea of two weeks duration. Following the fiberoptic bronchoscopy, antibiotic ther- Several days prior to the onset of these symptoms, a apy was discontinued, and steady improvement of both sore throat, coryza, and an oral ulceration were noticed clinical and laboratory parameters occurred. Subse- by the patient. Oral cephalosporin therapy was pre- quently, a chest film reflected clearing of the lung infil- scribed, but it was discontinued after a single dose when trates (Fig 3), and arterial blood gas values had normal- urticaria developed. Next, tetracycline (500 mg, four ized. Eight days after admission, immediately prior to times a day) was prescribed and taken for approximately discharge, the peripheral total eosinophil count decreased one week. All three symptoms improved in two to three to 1,000 cells/cu mm. days, but as they resolved, cough, chest pain, and dysp- At follow-up examination four months later, the pa- nea appeared and then worsened. The patient had rein- tients chest roentgenogram, arterial blood gas levels, stituted tetracycline therapy for approximately 48 hours and CBC (including peripheral smear) were normal. Two prior to hospital admission. years after discharge, he remained asymptomatic, and The medical history revealed that in March 1983, the serologic testing for human immunodeficiency virus was patient experienced an illness characterized by diarrhea, negative. weight loss of approximately 10 lb, and generalized mal- aise. Mild leukopenia and anemia also were present. Al- though definite diagnosis was not determined, the ill- Discussion ness resolved spontaneously. Since the recognition of AIDS in 1981, the disease Diffuse lung infiltration in a homosexual man without AIDS 1115 Fig 2. Histologic specimen demonstrates marked eosinophilie in- filtration I H and E stain, original magnification, ,‹ 400). The clinical presentation of our patient was strik- ingly similar to that of many patients with AIDS, that is, high-risk status, cough, dyspnea, fever, weight loss, hypoxemia, and bilateral lung infil- trates. There was no evidence of immunodeficiency or the presence of an opportunistic infection, but marked blood and lung eosinophilia was found. Fig 1. Admission chest roentgenogram reveals bilateral intersti- This case presentation demonstrates that diffuse tial alveolar infiltrates. infiltrates in homosexual men are not necessarily due to infectious opportunistic pneumonia, and that the differential diagnosis must be expanded to in- clude other diseases. has maintained its position as one of the most fas- cinating, yet worrisome, topics in pulmonary medi- cine. According to the Centers for Disease Control, AIDS can be diagnosed when a high-risk patient with either Kaposis sarcoma or an opportunistic infection such as P carinii pneumonia is found to have serious underlying immunodeficiency.2-4 Other opportunistic infections include cytomega- lovirus, candidiasis, Cryptococcus neoformans, her- pes simplex and herpes zoster, mycobacterial in- fection, cryptosporidiosis, and toxoplasmosis. 5 Non- specific symptoms and signs, including fever, lym- phadenopathy, and weight loss, may or may not be present. Besides the two major risk groups of male ho- mosexuals or bisexuals and intravenous drug abus- ers, additional risk subgroups include hemophili- acs and other blood product transfusion recipients, as well as sexual partners and infants of high-risk group members.6 Immunologic abnormalities in AIDS include a selective deficit of helper T-lymphocytes, reversal of the T-cell helper/suppressor ratio in the periph- eral blood, elevated levels of serum immunoglobu- lin from polyclonal B-cell activation, and cutane- Fig 3. Chest film obtained eight days following admission shows ous anergy.3.4 marked clearing of bilateral lung infiltrates. 1116 September 1988 Journal of AOA/vol. 88/no.9 The list of diseases associated with bilateral lung 1.Jaffe 11W, Choi K, Thomas PA, et al: National case-control study of infiltrates and eosinophilia has grown substantially Kaposis sarcoma and Pneumocystis cariniipneumonia in homosexual men: Part I—epidemiological results. Ann Intern Med 1983;99:145-151. since the initial descriptions by Loff ler7 in 1932. 2. Mintz L, Drew WL, Miner RC, et al: Cytomegalovirus infections in Recently, Lynch and Flint8 categorized these di- homosexual men: An epidemiological study. Ann Intern Med 1983;99:326- eases into seven distinct syndromes: eosinophilic 329. 3. Murray JF, Felton CP, Garay SM, et al: Pulmonary complications pneumonia, chronic eosinophilic pneumonia, para- of the acquired immunodeficiency syndrome: Report of a National Heart, sitic eosinophilic pneumonia, allergic bronchopul- Lung, and Blood Institute Workshop. N Engi J Med 1984;310:1682- 1688. monary aspergillosis, bronchocentric granuloma- 4. Groopman JE: Kaposis sarcoma and other neoplasms. Ann Intern Med tosis, mucoid impaction of bronchi, and allergic 1983;99:208-210. 5. Update on acquired immune deficiency syndrome (AIDS)—United angiitis and granulomatosis. The clinical course States. MMWR 1982;31:507-514. and histologic characteristics of the lung biopsy al- 6. Chamberland ME, Castro KG, Haverkas HW, et al: Acquired immu- lowed us to classify our case as acute eosinophilic nodeficiency syndrome in the United States: An analysis of cases out- side high-incidence groups. Ann Intern Med 1984;101:617-623. pneumonia. 7. Loffler W: Zur Differential Diagnose der Lungenin Filtrierungen: III. Recently, this type of pneumonic process has Uber Fluchtige Succedan Infiltrate (mit Eosinophilie). Beitr Klin Tu- been linked with exposure to various drugs and berk 1932;79:368-392. 8. Lynch JP III, Flint A: Sorting out the pulmonary eosinophilic syn- chemical agents, including penicillin,9 nitrofuran- dromes. J Resp Dis 1984;5(July):61-78. toin,10 and tetracycline. 11,12 Although the exact eti- 9. Reichlin S, Loveless MH, Kane EJ: Loefflers syndrome following peni- ology of our patients disease process remains ques- cillin therapy. Ann Intern Med 1953;38:113-120. 10.Hailey FJ, Glascock HW Jr, Hewitt WF: Pleuropneumonic reactions tionable, the possibility of tetracycline causing the to nitrofurantoin. N Engl J Med 1969;281:1087-1090. eosinophilic process must be considered. 11.Ho D, Thshkin DP, Bein ME, et al: Pulmonary infiltrates with eosin- ophilia associated with tetracycline. Chest 1979;76:33-36. 12.Otero M, Goodpasture HC: Pulmonary infiltrates and eosinophilia Summary from minocycline, letter. JAMA 1983;250:2602. Diffuse lung infiltrates in a homosexual man gen- erally represent opportunistic infection; however, From the Department of Internal Medicine, Division of Pulmo- in the case presented this was not true. Obtaining nary Medicine, University of lbxas Medical School, Houston, a specific diagnosis is essential for the proper man- Thx. agement and treatment of patients who present Reprint requests to Dr DAlonzo, 5431 Fannin, Suite 1.274, Hous- with diffuse lung infiltrates. ton, TX 77030. Diffuse lung infiltration in a homosexual man without AIDS 1117.
Load more

Recommended publications
  • ICD-10-CM Expert for SNF, IRF, and LTCH the Complete Official Code Set Codes Valid from October 1, 2018 Through September 30, 2019
    EXPERT 2019 ICD-10-CM Expert for SNF, IRF, and LTCH The complete official code set Codes valid from October 1, 2018 through September 30, 2019 Power up your coding optum360coding.com ITSN_ITSN19_CVR.indd 1 12/4/17 2:54 PM Contents Preface ................................................................................ iii ICD-10-CM Index to Diseases and Injuries .......................... 1 ICD-10-CM Official Preface ........................................................................iii Characteristics of ICD-10-CM ....................................................................iii ICD-10-CM Neoplasm Table ............................................ 331 What’s New for 2019 .......................................................... iv ICD-10-CM Table of Drugs and Chemicals ...................... 349 Official Updates ............................................................................................iv Proprietary Updates ...................................................................................vii ICD-10-CM Index to External Causes ............................... 397 Introduction ....................................................................... ix ICD-10-CM Tabular List of Diseases and Injuries ............ 433 History of ICD-10-CM .................................................................................ix Chapter 1. Certain Infectious and Parasitic Diseases (A00-B99) .........................................................................433 How to Use ICD-10-CM Expert for Skilled Nursing Chapter
    [Show full text]
  • 20) Thyrotoxicosis
    1 Міністерство охорони здоров’я України Харківський національний медичний університет Кафедра Внутрішньої медицини №3 Факультет VI по підготовці іноземних студентів ЗАТВЕРДЖЕНО на засіданні кафедри внутрішньої медицини №3 «29» серпня 2016 р. протокол № 13 Зав. кафедри _______д.мед.н., професор Л.В. Журавльова МЕТОДИЧНІ ВКАЗІВКИ для студентів з дисципліни «Внутрішня медицина (в тому числі з ендокринологією) студенти 4 курсу І, ІІ, ІІІ медичних факультетів, V та VI факультетів по підготовці іноземних студентів Тиреотоксикоз. Клінічні форми, діагностика, лікування. Пухлини щитоподібної залоз та патологія при щитоподібних залоз Харків 2016 2 Topic – «Thyrotoxicosis. Clinical forms, diagnostic, treatment. Tumors of thyreoid gland and pathology of parathyroid glands» 1.The number of hours - 5 Actuality: Thyroid gland disease is one of the most popular in Ukraine affect patients of working age, degrade the quality of life and reduce its duration. Aim: 1. To learn the method of determining the etiologic factors and pathogenesis of diffuse toxic goiter. Work out techniques of palpation of the thyroid gland. 2. To familiarize students with the classifications of goiter by OV.Nikolaєv (1955 г.) And WHO (1992 г.). 3. To distinguish a typical clinical picture of diffuse toxic goiter (DTG). 4. To acquainte with the atypical clinical variants of diffuse toxic goiter. 5. To acquaint students with the possible complications of DTG. 6. To determine the basic diagnostic criteria for Graves' disease 7. To make a plan to examinate patients with Graves' disease. 8. Analysis of the results of laboratory and instrumental studies, which are used for the diagnosis of DTG. 9. Differential diagnosis between DTG and goiter 10. Technology of formulation of the diagnosis of DTG and goiter.
    [Show full text]
  • European Conference on Rare Diseases
    EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia
    [Show full text]
  • Orphanet Rep Rt Series
    Prevalence of rare diseases : A bibliographic survey Orphanet February 2008 Rep rt Method Series By alphabetical list of diseases By decreasing prevalence By reported number of published cases Method A systematic survey of the literature is being performed in order to provide an estimate of the prevalence of rare diseases in Europe. An updated report will be published regularly and will replace the previous version. This update contains new epidemiological data and modifications to existing data for which new information has been made available. Search strategy The search strategy is carried out using several data sources: - Websites: Orphanet, e-medicine, GeneClinics, EMEA and OMIM - Medline is consulted using the search algorithm: «Disease names» AND [Epidemiology[MeSH:NoExp] OR Incidence[Title/abstract] OR Prevalence[Title/abstract] OR Epidemiology[Title/abstract] - Medical books, grey literature and reports from experts are also important sources of data. Collected data Prevalence values provided are the mean of the highest and lowest values collected. When prevalence is not documented we calculate it using incidence: - For congenital diseases with birth-onset, prevalence = incidence at birth x (patient life expectancy/general population life expectancy) - For the other rare diseases, prevalence = incidence x rare disease mean duration. NB: Life expectancy of the French population (78 years) is used as the general population life expectancy. Updated Data New information from available data sources: EMEA, new scientific publications, grey literature, expert opinion. Limitation of the study The exact prevalence rate of each rare disease is difficult to assess from the available data sources. There is a low level of consistency between studies, a poor documentation of methods used, confusion between incidence and prevalence, and/or confusion between incidence at birth and life-long incidence.
    [Show full text]
  • Regulations for Disease Reporting and Control
    Department of Health Regulations for Disease Reporting and Control Commonwealth of Virginia State Board of Health October 2016 Virginia Department of Health Office of Epidemiology 109 Governor Street P.O. Box 2448 Richmond, VA 23218 Department of Health Department of Health TABLE OF CONTENTS Part I. DEFINITIONS ......................................................................................................................... 1 12 VAC 5-90-10. Definitions ............................................................................................. 1 Part II. GENERAL INFORMATION ............................................................................................... 8 12 VAC 5-90-20. Authority ............................................................................................... 8 12 VAC 5-90-30. Purpose .................................................................................................. 8 12 VAC 5-90-40. Administration ....................................................................................... 8 12 VAC 5-90-70. Powers and Procedures of Chapter Not Exclusive ................................ 9 Part III. REPORTING OF DISEASE ............................................................................................. 10 12 VAC 5-90-80. Reportable Disease List ....................................................................... 10 A. Reportable disease list ......................................................................................... 10 B. Conditions reportable by directors of
    [Show full text]
  • Trachyonychia: a Comprehensive Review Part I
    Symposium-Nails Trachyonychia: A comprehensive review Part I Katherine A. Gordon, Janelle M. Vega, Antonella Tosti Department of Dermatology ABSTRACT and Cutaneous Surgery, University of Miami Miller Trachyonychia or rough nails, may present as an idiopathic disorder of the nails or it can School of Medicine, Miami, Florida, USA be associated with other dermatological conditions. The dystrophic nail findings seen in trachyonychia are characterized by brittle, thin nails, with excessive longitudinal ridging. Address for correspondence: The most common histopathologic features associated with trachyonychia are spongiosis Mrs. Katherine Gordon, and exocytosis of inflammatory cells into the nail epithelia; typical features of lichen planus Department of Dermatology or psoriasis can also be detected. Determining the cause of trachyonychia is challenging. and Cutaneous Surgery, Treatment is often unsatisfactory, although in general it should be aimed at the underlying University of Miami Miller cause, if found. In most cases, the nail abnormalities improve spontaneously. School of Medicine, 1600 N.W. 10th Avenue, RMSB, Room 2023-A, Key words: Trachyonychia, rough nails, twenty nail dystrophy Miami, Florida 33136, USA. E-mail: [email protected] INTRODUCTION and was termed twenty-nail dystrophy of childhood in 1977 by Hazelrigg, et al.[5,7] Trachyonychia is much Trachyonychia, derived from the Greek word trakos, more common in children, with an insidious onset and for rough, is a descriptive term referring to rough nail peak age of 3 to 12 years.[1,2] However, it can occur at changes.[1] We performed a thorough PubMed search any age.[6,8] Trachyonychia can be a manifestation of a for papers using MeSH terms “trachyonychia, rough pleomorphic group of disorders or can be idiopathic.[9] nails and twenty nail dystrophy”, and compiled this Table 1 provides a complete list of reported comprehensive review.
    [Show full text]
  • ICD-10 International Statistical Classification of Diseases and Related Health Problems
    ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • FAQ REGARDING DISEASE REPORTING in MONTANA | Rev
    Disease Reporting in Montana: Frequently Asked Questions Title 50 Section 1-202 of the Montana Code Annotated (MCA) outlines the general powers and duties of the Montana Department of Public Health & Human Services (DPHHS). The three primary duties that serve as the foundation for disease reporting in Montana state that DPHHS shall: • Study conditions affecting the citizens of the state by making use of birth, death, and sickness records; • Make investigations, disseminate information, and make recommendations for control of diseases and improvement of public health to persons, groups, or the public; and • Adopt and enforce rules regarding the reporting and control of communicable diseases. In order to meet these obligations, DPHHS works closely with local health jurisdictions to collect and analyze disease reports. Although anyone may report a case of communicable disease, such reports are submitted primarily by health care providers and laboratories. The Administrative Rules of Montana (ARM), Title 37, Chapter 114, Communicable Disease Control, outline the rules for communicable disease control, including disease reporting. Communicable disease surveillance is defined as the ongoing collection, analysis, interpretation, and dissemination of disease data. Accurate and timely disease reporting is the foundation of an effective surveillance program, which is key to applying effective public health interventions to mitigate the impact of disease. What diseases are reportable? A list of reportable diseases is maintained in ARM 37.114.203. The list continues to evolve and is consistent with the Council of State and Territorial Epidemiologists (CSTE) list of Nationally Notifiable Diseases maintained by the Centers for Disease Control and Prevention (CDC). In addition to the named conditions on the list, any occurrence of a case/cases of communicable disease in the 20th edition of the Control of Communicable Diseases Manual with a frequency in excess of normal expectancy or any unusual incident of unexplained illness or death in a human or animal should be reported.
    [Show full text]
  • Prioritizing Zoonotic Diseases for Multisectoral, One Health Collaboration in the United States Workshop Summary
    Prioritizing Zoonotic Diseases for Multisectoral, One Health Collaboration in the United States Workshop Summary CS29887A ONE HEALTH ZOONOTIC DISEASE PRIORITIZATION WORKSHOP REPORT, UNITED STATES Photo 1. A brown bear in the forest. ii ONE HEALTH ZOONOTIC DISEASE PRIORITIZATION WORKSHOP REPORT, UNITED STATES TABLE OF CONTENTS Participating Organizations ........................................................................................................................................................... iv Executive Summary ............................................................................................................................................................................. 1 Background ............................................................................................................................................................................................ 21 Workshop Methods ....................................................................................................................................................................... 30 Recommendations for Next Steps ........................................................................................................................................... 35 APPENDIX A: Overview of the One Health Zoonotic Disease Prioritization Process ................................ 39 APPENDIX B: One Health Zoonotic Disease Prioritization Workshop Participants for the United States ...............................................................................................................................................................................
    [Show full text]
  • History of the Statistical Classification of Diseases and Causes of Death
    Copyright information All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated. Suggested citation Moriyama IM, Loy RM, Robb-Smith AHT. History of the statistical classification of diseases and causes of death. Rosenberg HM, Hoyert DL, eds. Hyattsville, MD: National Center for Health Statistics. 2011. Library of Congress Cataloging-in-Publication Data Moriyama, Iwao M. (Iwao Milton), 1909-2006, author. History of the statistical classification of diseases and causes of death / by Iwao M. Moriyama, Ph.D., Ruth M. Loy, MBE, A.H.T. Robb-Smith, M.D. ; edited and updated by Harry M. Rosenberg, Ph.D., Donna L. Hoyert, Ph.D. p. ; cm. -- (DHHS publication ; no. (PHS) 2011-1125) “March 2011.” Includes bibliographical references. ISBN-13: 978-0-8406-0644-0 ISBN-10: 0-8406-0644-3 1. International statistical classification of diseases and related health problems. 10th revision. 2. International statistical classification of diseases and related health problems. 11th revision. 3. Nosology--History. 4. Death- -Causes--Classification--History. I. Loy, Ruth M., author. II. Robb-Smith, A. H. T. (Alastair Hamish Tearloch), author. III. Rosenberg, Harry M. (Harry Michael), editor. IV. Hoyert, Donna L., editor. V. National Center for Health Statistics (U.S.) VI. Title. VII. Series: DHHS publication ; no. (PHS) 2011- 1125. [DNLM: 1. International classification of diseases. 2. Disease-- classification. 3. International Classification of Diseases--history. 4. Cause of Death. 5. History, 20th Century. WB 15] RB115.M72 2011 616.07’8012--dc22 2010044437 For sale by the U.S.
    [Show full text]
  • Neglected Diseases
    Neglected Diseases What is a neglected disease? Why do we call these diseases neglected? How many people are affected by neglected diseases? What are some examples of neglected diseases? What can be done to prevent neglected diseases? How can neglected diseases be treated? Where can people get more information about neglected diseases? What is a neglected disease? Neglected diseases are conditions that inflict severe health burdens on the world’s poorest people. Many of these conditions are infectious diseases that are most prevalent in tropical climates, particularly in areas with unsafe drinking water, poor sanitation, substandard housing and little or no access to health care. Why do we call these diseases neglected? Diseases are said to be neglected if they are often overlooked by drug developers or by others instrumental in drug access, such as government officials, public health programs and the news media. Typically, private pharmaceutical companies cannot recover the cost of developing and producing treatments for these diseases. Another reason neglected diseases are not considered high priorities for prevention or treatment is because they usually do not affect people who live in the United States and other developed nations. Neglected diseases also lack visibility because they usually do not cause dramatic outbreaks that kill large numbers of people. Rather, such diseases usually exact their toll over a longer period of time, leading to crippling deformities, severe disabilities and/or relatively slow deaths. How many people are affected by neglected diseases? The World Health Organization (WHO) estimates that more than 1 billion people -- one- sixth of the world’s population -- suffer from one or more neglected diseases.
    [Show full text]
  • Infectious Diseases in Child Care and School Settings
    Infectious Diseases in Child Care and School Settings Guidelines for CHILD CARE PROVIDERS, SCHOOL NURSES AND OTHER PERSONNEL Communicable Disease Branch 4300 Cherry Creek Drive South Denver, Colorado 80246-1530 Phone: (303) 692-2700 Fax: (303) 782-0338 Updated March 2016 1 Acknowledgements These guidelines were compiled by the Communicable Disease Branch at the Colorado Department of Public Health and Environment. We would like to thank many subject matter experts for reviewing the document for content and accuracy. We would also like to acknowledge Donna Hite; Rene’ Landry, RN, BSN; Kate Lujan, RN, MPH; Kathy Patrick, RN, MA, NCSN, FNASN; Linda Satkowiak, ND, RN, CNS, NCSN; Jennifer Ward, RN, BSN; and Cathy White, RN, MSN for their comments and assistance in reviewing these guidelines. Special thanks to Heather Dryden, Administrative Assistant in the Communicable Disease Branch, for expert formatting assistance that makes this document readable. Revisions / Updates Date Description of Changes Pages/Sections Affected 2012 Major revision to content and format; combine previous Throughout separate guidance documents for child care and schools into one document Dec 2014 Updated web links due to CDPHE website change; updated Throughout several formatting issues; added hyperlinks to table of contents; no content changes May 2015 Added updated FERPA letter from the CO Dept of Education; Introduction added links to additional info to the animal contact section in the introduction; added new bleach concentration disinfection guidance Oct 2015
    [Show full text]